Endologix revealed today that Dr. Matt Thompson, the company’s President and CEO, plans to vacate his current position to assume the role of EVP and chief medical officer. This transition paves the way for Dr. John Liddicoat, who has been appointed as the new president and CEO with immediate effect.
Richard Mott, Chairman of the Board at Endologix, highlighted the announcement as Thompson expresses his wish to devote more time to the UK.
Based in Irvine, California, Endologix specializes in developing treatments for arterial diseases, including the Detour system designed for peripheral arterial disease (PAD) care.
With over three decades of healthcare expertise globally, Liddicoat brings a wealth of knowledge to the table. His tenure at Medtronic spanned over 16 years, where he held various leadership positions, directing strategic plans and managing worldwide operations for segments such as cardiac rhythm and heart failure.
“We are delighted to have Dr. John Liddicoat join us as our CEO,” expressed Mott. “His deep-rooted experience and leadership in the healthcare sector make him the perfect candidate to lead Endologix into its upcoming phase of growth and innovation. Additionally, our gratitude goes out to Matt for his distinguished leadership and the remarkable progress achieved under his guidance as CEO. It’s gratifying to know that Matt will continue to play an integral role within our organization, allowing him to align his career with personal commitments in the UK.”